Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.48 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.42 |
| ▸ | GCGR | P47871 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | VHL | P40337 | 1/20 | 0.37 |
| ▸ | ELOC | Q15369 | 1/20 | 0.37 |
| ▸ | ELOB | Q15370 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.36 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1549833 | 0.84 | NOTUM (0.55) | NOTUMCYP11B1CYP11B2CYP19A1ALKBH1 | |
| SCHEMBL21753342 | 0.84 | CYP19A1 (0.40) | NOTUMCYP11B1CYP11B2GCGRACACB | |
| SCHEMBL7259245 | 0.82 | QPCT (0.45) | GCGRACACBALKBH1EGLN1 | |
| SCHEMBL1682507 | 0.81 | CA12 (0.47) | NOTUMGCGRCYP19A1GAASCN9A | |
| SCHEMBL28241532 | 0.78 | MAOB (0.39) | NOTUMCYP11B1CYP11B2GCGRCYP19A1 | |
| SCHEMBL2214866 | 0.78 | GAA (0.53) | ACACBGAA | |
| SCHEMBL21525502 | 0.76 | HPGDS (0.53) | GCGR | |
| SCHEMBL25365261 | 0.75 | NOTUM (0.44) | NOTUMGCGRVHLELOCELOB | |
| SCHEMBL15729239 | 0.75 | VHL (0.40) | NOTUMGCGRVHLELOCELOB | |
| SCHEMBL21753234 | 0.75 | KMT2A (0.47) | VHLELOCELOBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12016852-B2 | Pyrrolidine glycosidase inhibitors | ASCENEURON SA (CH) | 2024-06-25 | — | — | US | disclosed |
| US-12016852-B2 | Pyrrolidine glycosidase inhibitors | ASCENEURON SA (CH) | 2024-06-25 | — | — | US | disclosed |
| US-20210213005-A1 | PYRROLIDINE GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2021-07-15 | — | — | US | disclosed |
| US-20210213005-A1 | PYRROLIDINE GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2021-07-15 | — | — | US | disclosed |
| WO-2020039027-A1 | PYRROLIDINE GLYCOSIDASE INHIBITORS | ASCENEURON S. A. (CH) | 2020-02-27 | — | — | WO | disclosed |
| WO-2020039027-A1 | PYRROLIDINE GLYCOSIDASE INHIBITORS | ASCENEURON S. A. (CH) | 2020-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12016852-B2 | Pyrrolidine glycosidase inhibitors | PREP, GAA, DNPEP | NOTUM 476/4885CYP11B1 2519/4885CYP11B2 2659/4885 |
| US-20210213005-A1 | PYRROLIDINE GLYCOSIDASE INHIBITORS | PREP, GAA, DNPEP | NOTUM 358/4885CYP11B1 2625/4885CYP11B2 2834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.